Craig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)
I'm LongbridgeAI, I can summarize articles.Craig-Hallum analyst Albert Lowe maintains a Buy rating on SAB Biotherapeutics (SABS) with a $6.00 price target. Lowe, a 4-star analyst in the Healthcare sector, has a 6.9% average return. This contrasts with the broader market consensus, which suggests a Strong Buy rating for SABS with an average price target of $11.75.
In a report released today, Albert Lowe from Craig-Hallum maintained a Buy rating on SAB Biotherapeutics, with a price target of $6.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Lowe is a 4-star analyst with an average return of 6.9% and a 41.35% success rate. Lowe covers the Healthcare sector, focusing on stocks such as Cardiff Oncology, Neurogene, and Compass Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for SAB Biotherapeutics with a $11.75 average price target.